Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide

Leukemia Research

Volumn 29, Issue 8, 2005, Pages 967-969

  Strupp, C ^a   Fenk, R ^a   Kundgen A ^a   Gattermann, N ^a   Haas, R ^a   Germing, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Hairy cell leukemia; Myelofibrosis; Thalidomide

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CLADRIBINE; GLYCOPROTEIN P 15095; HEMOGLOBIN; THALIDOMIDE;

AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; DRUG RESPONSE; HAIRY CELL LEUKEMIA; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LYMPHOCYTIC INFILTRATION; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; POLYNEUROPATHY; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTOPENIA; TRANSFUSION;

AGED; CLADRIBINE; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MYELOFIBROSIS; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 20544441469     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.01.007     Document Type: Article

References (21)

1. U. Jehn, R. Bartl, H. Dietzfelbinger, T. Haferlach, and V. Heinemann An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine Leukemia 18 2004 1476 1481
2. M. Shehata, J.D. Schwarzmeier, M. Hilgarth, R. Hubmann, M. Duechler, and H. Gisslinger TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia J Clin Invest 113 2004 676 685
3. K.A. Aziz, K.J. Till, H. Chen, J.R. Slupsky, F. Campbell, and J.C. Cawley The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL) Blood 102 2003 1051 1056 [Epub., April 10, 2003]
4. G. Gruber, J.D. Schwarzmeier, M. Shehata, M. Hilgarth, and R. Berger Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia Blood 94 1999 1077 1085
5. K.A. Aziz, K.J. Till, M. Zuzel, and J.C. Cawley Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia Blood 96 2000 3161 3167
6. P. Korkolopoulou, D.A. Gribabis, N. Kavantzas, M.K. Angelopoulou, M.P. Siakantaris, and E. Patsouris A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations Br J Haematol 122 2003 900 910
7. G. Pruneri, F. Bertolini, L. Baldini, S. Valentini, M. Goldaniga, and D. Soligo Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12 Br J Haematol 120 2003 695 698
8. R.A. Mesa, M.A. Elliott, G. Schroeder, and A. Tefferi Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia Mayo Clin Proc 79 2004 883 889
9. P.P. Piccaluga, G. Visani, S.A. Pileri, S. Ascani, T. Grafone, and A. Isidori Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study Leukemia 16 2002 1609 1614
10. G. Damaj, F. Lefrere, R. Delarue, B. Varet, R. Furman, and O. Hermine Thalidomide therapy induces response in relapsed mantle cell lymphoma Leukemia 17 2003 1914 1915
11. H. Kaufmann, M. Raderer, S. Woehrer, A. Puespoek, A. Bankier, and C. Zielinski Anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Blood May 27 2004 [Epub. ahead of print]
12. B. Pro, A. Younes, M. Albitar, N.H. Dang, F. Samaniego, and J. Romaguera Thalidomide for patients with recurrent lymphoma Cancer 100 2004 1186 1189
13. C. Sugimori, K. Kaito, and S. Nakao Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports Int J Hematol 77 2003 391 394
14. K. Dedic, and P. Zak Effect of 2-chlorodeoxyadenosine therapy on bone marrow fibrosis in hairy cell leukemia Neoplasma 51 2004 56 58
15. E. Crivellato, B. Nico, A. Vacca, and D. Ribatti B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization Haematologica 88 2003 671 678
16. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
17. L.G. Corral, and G. Kaplan Immunomodulation by thalidomide and thalidomide analogues Am Rheum Dis 58 1999 107 113
18. J.B. Marriot, I.A. Clarke, K. Dredge, G. Muller, D. Stirling, and A.G. Dalgleish Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells Clin Exp Immunol 130 2002 75 84
19. S. Singhal, J. Metha, R. Desikan, D. Ayers, P. Roberson, and P. Eddlemon Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
20. C. Strupp, U. Germing, M. Aivado, E. Misgeld, R. Haas, and N. Gattermann Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia 16 2002 1 6
21. C. Strupp, M. Aivado, U. Germing, N. Gattermann, and R. Haas Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports Leuk Lymph 43 2002 133 137